Elanco Animal Health, spun off from Eli Lilly in 2018, told investors its revenue growth reflected strong consumer demand for its pet-health and farm-animal products. The SEC found that a significant part of that growth came from quarter-end incentivized sales to distributors — rebates and extended payment terms that pulled forward revenue and built excess inventory in the channel.
Elanco did not disclose that its growth depended on these incentives, or the reasonably likely risk that the channel inventory would depress future revenue. Its periodic reports and earnings releases were inaccurate or incomplete as a result.
In November 2024 Elanco agreed to pay a $15 million civil penalty and accept a cease-and-desist order.
Elanco paid a $15M SEC penalty for calling channel-stuffing 'strong demand' — incentives pulled forward revenue, and undisclosed inventory risk depressed future sales.
Quarter-end incentives are the fastest way to hit a revenue target, and the cost — future revenue pulled forward — does not show up until the next quarter.
Telling investors the growth was demand-driven made the numbers look sustainable when they were not.
Channel inventory is invisible to the income statement until the distributor stops ordering.
Revenue bought with quarter-end incentives is a loan from next quarter — and the investors you tell it is demand are the ones who will notice when the loan comes due.
FOLLOW THE EVIDENCE